IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies
Christian Leborgne(Inserm), Elena Barbon(Inserm), J M Alexander(Spark Therapeutics (United States)), Hayley A. Hanby(Spark Therapeutics (United States)), Sandrine Delignat(Inserm), Daniel M. Cohen(Spark Therapeutics (United States)), Fanny Collaud(Inserm), Saghana Muraleetharan(Spark Therapeutics (United States)), Dan Lupo(Spark Therapeutics (United States)), Joseph Silverberg(Spark Therapeutics (United States)), Karen Huang(Spark Therapeutics (United States)), Laetitia van Wittengerghe(Inserm), Béatrice Marolleau(Inserm), Adeline Miranda(Inserm), Anna Fabiano(Inserm), Victoria Daventure(Inserm), Heena Beck(Spark Therapeutics (United States)), Xavier M. Anguela(Spark Therapeutics (United States)), Giuseppe Ronzitti(Inserm), Sean M. Armour(Spark Therapeutics (United States)), Sébastien Lacroix‐Desmazes(Université Paris Cité), Federico Mingozzi(Université Paris-Saclay)
Cited by 311Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis